Table 2. Base Case Results.

Strategy	Cost, $	LYG	Incremental cost, $	Incremental LYG	ICER, $/LYGa	Total cancer, %b	Deaths due to cancer, %b
Natural history	6284	35.574	[Referenc]	[Reference]	[Reference]	5.2	1.6
FIT	8223	35.624	1939	0.050	Extendedly dominatedc	4.2	1.2
Colonoscopy	9037	35.672	2753	0.098	28 071	3.2	1.0
Stool DNA	11 583	35.641	2546	−0.031	Strictly dominatedd	3.7	1.1
Colonoscopy–LB	12 006	35.680	2969	0.008	377 538	3.0	0.9
LB	15 562	35.581	3555	−0.099	Strictly dominatedd	5.1	1.5

Abbreviations: ICER, incremental cost-effectiveness ratio; FIT, fecal immunochemical test; LB, liquid biopsy; LYG, life-years gained.

^a ICER is calculated relative to the next least costly, nondominated strategy.

^b Total cancer and deaths due to cancer represent cancer incidence and mortality of the entire population.

^b Extendedly dominated indicates that the strategy resulted in fewer LYG at a higher cost per life-year gained compared with another strategy.

^d Strictly dominated indicates that the strategy resulted in higher costs and fewer LYG compared with another strategy.